OBJECTIVES: Assess if the current health systems have the tools to fund an increasing flow of new potentially curative interventions such as gene/cell therapies

METHODS: Confidential poll using an instant electronic voting system with self-selected participants made of a mix of industry executives, patient association representatives, R&D researchers, consultants and investors attending a panel discussion organised by CRA during BioEurope Amsterdam 2018

RESULTS: CONCLUSIONS: Managed Entry Agreements have been a traditional option for stakeholders negotiating price and access of new medicine. It has been used in many markets to ensure otherwise compromised or delayed access for some new treatments. Although opinion was not unanimous, the vast majority of participants perceive that paying for the access of the emerging gene/cell therapy is different. Potentially curative treatment for very limited and very often not expandable population will expose the limitation of existing HTA and funding models. All stakeholders involved and or influencing pricing and access decisions should therefore continue to seek innovative long-term mutually beneficial solutions. Options will have to go beyond the simple and obvious past choices. Negotiating solutions will require a level of complexity not seen before and will require reaching agreement on many uncertainties.